All of us at Breast Cancer Now are delighted to hear that Professor Andrew Tutt, Director of the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research and the Breast Cancer Now Research Unit at King’s College London, has been elected as a Fellow of the Academy of Medical Sciences.
The Academy's fellowship
The Academy’s prestigious fellowships are awarded to the UK’s leading figures in biomedical and health sciences to recognise their outstanding contribution to advancing research progress and translating this progress into benefits for patients and wider society.
Professor Tutt, who has been Director of the Breast Cancer Now Research Centre since 2014, joins 49 other top biomedical and health scientists in fields including global health, virology, women’s health, medical statistics, cancer genetics, allergy and emergency care medicine in being appointed as a Fellow this year.
Professor Tutt's research
The fellowship recognises Professor Tutt’s exceptional contribution to developing our understanding of breast cancer, as well as his role in translating discoveries in the lab into benefits for patients. Among his achievements, Professor Tutt has been involved in the development and clinical testing of PARP inhibitors such as olaparib, a targeted treatment which specifically kills cancer cells with faults in BRCA genes. Olaparib has been approved by the FDA to be given to people with BRCA mutated secondary breast cancer in the USA and the NICE appraisal is due to start later in 2019.
In addition to this, he has also shown that the chemotherapy drug carboplatin is more beneficial for people living with incurable triple negative breast cancer who carry a BRCA mutation. Carboplatin provides these people with two and half months of extra time before their disease gets worse, compared to standard chemotherapy.
Professor Andrew Tutt, Director of the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, London, said:
It’s a great honour to be elected to the Academy of Medical Sciences alongside so many other prestigious scientists who are changing the landscape of public health to improve the lives of patients and carers.
It has been a privilege working with so many talented scientists, clinical trialists and very brave and inspiring patients to harness biology to treat breast cancer in a more personalised, targeted and effective way. I am proud of how far we have come as a team in advancing our understanding of these diverse diseases.
Dr Simon Vincent, Director of Research at Breast Cancer Care and Breast Cancer Now, said:
We are delighted to see that Professor Andrew Tutt has been elected as a Fellow of the Academy of Medical Sciences. These Fellowships highlight the contributions biomedical researchers are making within their respective fields and Professor Tutt’s achievements within breast cancer research have been exceptional.
Thanks to Andrew’s leadership, we now know much more about breast cancer as a disease and how to treat it. The results from the Triple Negative Trial, which showed that carboplatin chemotherapy offers a long-awaited advance for people with triple negative breast cancer who carry a BRCA mutation, is just one example of the incredible and practice-changing impact of his teams’ research.
We would like to thank Andrew for his outstanding and ongoing contribution to the work of Breast Cancer Care and Breast Cancer Now and we look forward to working with him in the years to come.
In addition to Professor Tutt, we are proud to be funding several other prominent researchers who have been elected as Fellows of the Academy of Medical Sciences in previous years. This includes the leader of the Breast Cancer Now Generations Study Professor Anthony Swerdlow, Breast Cancer Now Trustee and grant holder Professor Adrian Harris, and research team leaders Professor Clare Isacke, Professor Mitch Dowsett and Professor Tony Ng.
About the Academy of Medical Sciences
The Academy of Medical Sciences is one of the UK’s National Academies, aiming to improve health within society by investing in, and supporting leading figures within the biomedical and health sciences.
Our research projects
Our research is focused on four key areas – risk and prevention, early detection and diagnosis, treatment and secondary breast cancer. We believe this approach will help us acheive our abition that by 2050, anyone diagnosed with breast cancer will live and live well.